Samsara Bio Capital, LLC Centessa Pharmaceuticals PLC Transaction History

Samsara Bio Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$3.68 - $6.9 $6.23 Million - $11.7 Million	-1,693,736 Closed	0 $0
Q1 2023 May 15, 2023	BUY	$3.03 - $4.0 $5.13 Million - $6.77 Million	1,693,736 New	1,693,736 $6.52 Million
Q2 2022 Aug 15, 2022	SELL	$3.18 - $9.85 $605,344 - $1.88 Million	-190,360 Reduced 10.1%	1,693,736 $8.25 Million
Q1 2022 May 16, 2022	BUY	$7.45 - $11.59 $3.16 Million - $4.92 Million	424,403 Added 29.07%	1,884,096 $16.9 Million
Q4 2021 Feb 14, 2022	SELL	$10.99 - $17.54 $855,461 - $1.37 Million	-77,840 Reduced 5.06%	1,459,693 $16.4 Million
Q2 2021 Aug 17, 2021	BUY	$21.71 - $25.66 $33.4 Million - $39.5 Million	1,537,533 New	1,537,533 $34.1 Million

108

118M

5.9K

53K

Ticker CNTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,339,296
Market Cap $1.59B
Description
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...

Get notified when there are updates to the investment portfolio of Samsara Bio Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Samsara Bio Capital, LLC with notifications on news.